BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sedano R, Guizzetti L, McDonald C, Jairath V. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing. Clin Gastroenterol Hepatol 2021;19:1497-1498.e1. [PMID: 32763479 DOI: 10.1016/j.cgh.2020.07.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Dalal RS, Allegretti JR. Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflamm Bowel Dis 2021;27:e70. [PMID: 33570151 DOI: 10.1093/ibd/izab019] [Reference Citation Analysis]
2 Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01084-3. [PMID: 34628078 DOI: 10.1016/j.cgh.2021.10.002] [Reference Citation Analysis]
3 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
4 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aguiar Zdovc J, Hanžel J, Kurent T, Sever N, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Ostanek B, Drobne D, Grabnar I. Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 2021;13:1587. [PMID: 34683880 DOI: 10.3390/pharmaceutics13101587] [Reference Citation Analysis]